4 reports

  • Dyslipidemia Market - Drivers and Barriers in the 5EU, 2015-2025
  • NATIONAL PUBLIC HEALTH INITIATIVES IN THE 5EU NATIONS

PharmaPoint: Dyslipidemia - Global Drug Forecast and Market Analysis to 2025 Summary Sales of dyslipidemia therapeutics is estimated to be approximately $11.2B across the 7MM in 2015, encompassing the US, 5EU, and Japan. The dyslipidemia market will grow at a strong CAGR of 10.1% over the forecast period, reaching...

  • Cholesterol
  • AstraZeneca PLC
  • Cerenis
  • Merck & Co., Inc.
  • The Medicines Company
  • DYSLIPIDEMIA MARKET - 5EU DRIVERS AND BARRIERS, 2014
  • NATIONAL HEALTHCARE AUTHORITIES IN THE 5EU NATIONS

Dyslipidemia - 5EU Drug Forecast and Market Analysis to 2023 Summary GlobalData estimates that the total market size for the 8MM in 2013 was $15.4bn, comprised of $11.0bn in branded drug sales (72%) and $4.4bn in generic sales (28%). GlobalData expects that the dyslipidemia drug market will grow at a CAGR of 9.4% over...

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

S##. and Rehabilitation; ##(##): ##-##.

  • Cholesterol
  • World
  • AstraZeneca PLC
  • Merck & Co., Inc.
  • Pfizer Inc.

Core operating income was USD ##. ## billion (-##%, +##% cc).

  • Cholesterol
  • Clinical Trial
  • Diagnostics
  • United States
  • GlobalData's company